Resonium-A

Country: New Zealand

Language: English

Source: Medsafe (Medicines Safety Authority)

Active ingredient:

Sodium polystyrene sulfonate 99.934% (Binding capacity 3.1mEq/g);  ;  

Available from:

Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics

INN (International Name):

Sodium polystyrene sulfonate 99.934% (Binding capacity 3.1mEq/g)

Dosage:

3.1 mEq/g

Pharmaceutical form:

Powder for oral solution

Composition:

Active: Sodium polystyrene sulfonate 99.934% (Binding capacity 3.1mEq/g)     Excipient: Saccharin sodium Vanillin

Units in package:

Bottle, plastic, 454 g

Class:

Prescription

Prescription type:

Prescription

Manufactured by:

Purolite SA

Therapeutic indications:

Treatament of hyperkalaemia.

Product summary:

Package - Contents - Shelf Life: Bottle, plastic, - 454 g - 36 months from date of manufacture stored at or below 30°C

Authorization date:

1969-12-31

Patient Information leaflet

Resonium A
®
1
RESONIUM A®
CONSUMER MEDICINE INFORMATION (CMI) SUMMARY
The full CMI on the next page has more details. If you are worried
about using this medicine, speak to your doctor or pharmacist.
1.
WHY AM I USING RESONIUM A?
Resonium A contains the active ingredient sodium polystyrene
sulfonate. Resonium A is used to help remove excessive amounts
of potassium from the blood. For more information, see Section 1. Why
am I using Resonium A? in the full CMI.
2.
WHAT SHOULD I KNOW BEFORE I USE RESONIUM A?
Do not use if you have ever had an allergic reaction to Resonium A or
any of the ingredients listed at the end of the CMI, have a
bowel obstruction, or have low levels of potassium. TALK TO YOUR
DOCTOR IF YOU HAVE ANY OTHER MEDICAL CONDITIONS, TAKE ANY OTHER
MEDICINES, OR ARE PREGNANT OR PLAN TO BECOME PREGNANT OR ARE
BREASTFEEDING. For more information, see Section
2. What should
I know before I use Resonium A? in the full CMI.
3.
WHAT IF I AM TAKING OTHER MEDICINES?
Some medicines may interfere with Resonium A and affect how it works.
A list of these medicines is in Section 3. What if I am
taking other medicines? in the full CMI.
4.
HOW DO I USE RESONIUM A?
•
Resonium A can be given by mouth or rectally (via the back passage).
•
The usual oral doses are 15 g three to four times daily for adults,
and 1 g/kg of body weight in divided doses for children.
Take Resonium A at least 3 hours before or 3 hours after other oral
medications.
•
The usual rectal (back passage) doses are 30 - 50 g in 150 mL of water
or 10% dextrose in water, as a retention enema for
adults, with lower dosages usually used for infants and children. Your
pharmacist will make this up. For infants and children,
this enema will usually be given by a doctor or nurse.
More instructions can be found in Section 4. How do I use Resonium A?
in the full CMI.
5.
WHAT SHOULD I KNOW WHILE USING RESONIUM A?
THINGS YOU
SHOULD DO
•
Remind any doctor, dentist or pharmacist you visit that you are using
Resonium A.
•
Be sure to keep all of your app

Summary of Product characteristics

New Zealand Data Sheet
Resonium - Sodium polystyrene sulfonate
resonium-a-ccdsv7-dsv7-01jul22
Page 1
NEW ZEALAND DATA SHEET
1
PRODUCT NAME
Resonium A powder 3.1mEq/g.
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Resonium A contains 99.93% sodium polystyrene sulfonate, saccharin
sodium and vanillin.
The sodium content is approximately 4.1mmol (100 mg) per gram of
Resonium A.
For the full list of excipients, see Section 6.1 List of excipients.
3
PHARMACEUTICAL FORM
Buff coloured powder.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of hyperkalaemia.
4.2
DOSE AND METHOD OF ADMINISTRATION
Resonium A is for oral or rectal administration only. The dosage
recommendations detailed below
are a guide only; the precise requirements should be determined on the
basis of regular clinical
and serum electrolyte monitoring.
_ADULTS _
Oral
15 g three to four times daily. Each dose should be given as a
suspension in a small amount of
water or, for greater palatability, in syrup (but not fruit juices,
which contain potassium), in the
ratio of 3-4 mL per gram of resin.
New Zealand Data Sheet
Resonium - Sodium polystyrene sulfonate
resonium-a-ccdsv7-dsv7-01jul22
Page 2
Administer at least 3 hours before or 3 hours after other oral
medications. For patients with
gastroparesis, a 6-hour separation should be considered (see Section
4.4 and Section 4.5).
Rectal
In cases where vomiting or upper gastrointestinal problems, including
paralytic ileus, may make
oral administration difficult, Resonium A may be given rectally in a
suspension of 30 g to 50 g
resin in 150 mL water or 10% dextrose in water, given as a daily
retention enema. In the initial
stages, administration by this route as well as orally may help to
achieve a more rapid lowering of
the serum potassium level.
The enema should if possible be retained for at least nine hours,
following which the colon should
be irrigated to remove the resin. If both routes are used at first, it
is probably unnecessary to
continue rectal administration once the oral resin has reached t